10,067 Shares in LivaNova PLC (NASDAQ:LIVN) Acquired by Entropy Technologies LP

Entropy Technologies LP purchased a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,067 shares of the company's stock, valued at approximately $529,000.

Several other institutional investors have also added to or reduced their stakes in the business. Primecap Management Co. CA boosted its holdings in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company's stock worth $327,889,000 after acquiring an additional 44,049 shares in the last quarter. Vanguard Group Inc. boosted its holdings in LivaNova by 3.5% in the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company's stock worth $102,537,000 after acquiring an additional 62,480 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in LivaNova by 204.3% in the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock worth $70,479,000 after acquiring an additional 863,157 shares in the last quarter. Magnetar Financial LLC boosted its holdings in LivaNova by 8.1% in the second quarter. Magnetar Financial LLC now owns 814,452 shares of the company's stock worth $44,648,000 after acquiring an additional 61,114 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock worth $41,889,000 after purchasing an additional 25,277 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

LIVN has been the subject of a number of research reports. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Saturday. Stifel Nicolaus lifted their target price on LivaNova from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Mizuho decreased their price target on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. Robert W. Baird boosted their price target on LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $75.00 price target on shares of LivaNova in a report on Tuesday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $69.17.

LivaNova Trading Down 0.4 %

Shares of LivaNova stock traded down $0.22 during trading hours on Friday, hitting $52.10. The company's stock had a trading volume of 357,203 shares, compared to its average volume of 618,280. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47. The firm has a fifty day moving average of $51.77 and a 200-day moving average of $52.95. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of 124.05 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.